CN114956974A - 一类倍半萜聚酮化合物、药物组合物及其用途 - Google Patents
一类倍半萜聚酮化合物、药物组合物及其用途 Download PDFInfo
- Publication number
- CN114956974A CN114956974A CN202210626229.0A CN202210626229A CN114956974A CN 114956974 A CN114956974 A CN 114956974A CN 202210626229 A CN202210626229 A CN 202210626229A CN 114956974 A CN114956974 A CN 114956974A
- Authority
- CN
- China
- Prior art keywords
- formula
- sesquiterpene
- polyketide
- disease
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Sesquiterpene polyketide Chemical class 0.000 title claims abstract description 34
- 229930001119 polyketide Natural products 0.000 title claims abstract description 30
- 229930004725 sesquiterpene Natural products 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 239000002955 immunomodulating agent Substances 0.000 claims abstract description 14
- 229940121354 immunomodulator Drugs 0.000 claims abstract description 14
- 230000002584 immunomodulator Effects 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 73
- 102000003814 Interleukin-10 Human genes 0.000 claims description 19
- 108090000174 Interleukin-10 Proteins 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 18
- 102100033461 Interleukin-17A Human genes 0.000 claims description 18
- 239000011734 sodium Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 241000223251 Myrothecium Species 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 208000009137 Behcet syndrome Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 206010046851 Uveitis Diseases 0.000 claims description 4
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 230000009286 beneficial effect Effects 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 201000011486 lichen planus Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 201000008383 nephritis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 125000003172 aldehyde group Chemical group 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010072268 Drug-induced liver injury Diseases 0.000 claims description 2
- 208000027761 Hepatic autoimmune disease Diseases 0.000 claims description 2
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims description 2
- 206010050296 Intervertebral disc protrusion Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 239000003978 infusion fluid Substances 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 150000003951 lactams Chemical group 0.000 claims description 2
- 150000002596 lactones Chemical group 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 238000002474 experimental method Methods 0.000 abstract description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 26
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 102000004388 Interleukin-4 Human genes 0.000 description 16
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 9
- 208000026278 immune system disease Diseases 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 210000000068 Th17 cell Anatomy 0.000 description 4
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000001965 potato dextrose agar Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 159000000009 barium salts Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 150000002505 iron Chemical class 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 230000005427 lymphocyte apoptotic process Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 101150074703 sun gene Proteins 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
- C07C47/57—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups polycyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/757—Unsaturated compounds containing a keto groups being part of a ring containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/18—Acetic acid esters of trihydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
- C12P7/26—Ketones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
- C07C2602/28—Hydrogenated naphthalenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一类可用作免疫调节剂的倍半萜聚酮化合物或药物组合物。活性实验显示本发明涉及的倍半萜聚酮类化合物，可作为免疫调节剂用于免疫相关疾病的预防和/或治疗。
Description
技术领域
本发明属于天然药物领域，更具体的涉及一类倍半萜聚酮化合物、药物组合物及其作为免疫调节剂和防治免疫性疾病的用途。
背景技术
免疫系统平衡对身体健康至关重要，当其被打破时容易患免疫性疾病。肿瘤和感染与机体免疫低下相关。器官移植免疫排斥、过敏和自身免疫病与机体免疫反应过强相关[1]，其中，自身免疫病包括炎症性肠病(IBD)、多发性硬化症(MS)和类风湿性关节炎(RA)在内的100余种疾病，发病重，发病率高，发病周期长，无治愈方法，严重危害人类健康。免疫调节剂可通过调节机体的免疫反应(增强、抑制或双向调节作用)，用于治疗免疫功能紊乱所引起的免疫性疾病。对于肿瘤和感染等与免疫力低下相关的疾病，可采用增强机体免疫力的调节剂进行干预。而对于器官移植免疫排斥、过敏和自身免疫病等与机体免疫反应过强相关的疾病，目前主要使用免疫抑制剂来改善疾病症状和预后。
皮质激素、甲氨蝶呤、环孢素A等化学药物属于非特异性免疫抑制剂，长期使用毒副作用大；生物制剂价格昂贵，治疗效果个体差异大，且具有增加病人感染与患肿瘤的风险。因此，开发新型免疫抑制剂来防治与免疫反应过强相关的疾病仍受到全世界的重视。近年来，我们对免疫性疾病的致病机制的研究取得了重要进展。抑制致炎因子IL17表达和促进抑炎因子IL10表达已成为抑制与免疫反应过强相关的免疫性疾病的有效策略，这为研发新型免疫抑制剂提供了新思路。
IL10是一类具有免疫抑制特性和广泛抗炎特性的细胞因子。IL10能调节多种髓系或淋系来源细胞的活性，抑制其产生促炎因子，从而发挥抑制器官移植免疫排斥、过敏、炎症以及自身免疫病的作用[4]。I型调节性T细胞(Tr1)分泌大量的IL10，是一类具有免疫抑制作用的细胞，目前，转输Tr1细胞防治自身免疫性疾病或保护器官移植免疫排斥的临床实验已现疗效[5]。
因此抑制IL17和/或促进IL10的化合物可作为免疫调节剂防治器官移植免疫排斥、过敏、炎症和自身免疫病(炎症性肠病、Ⅰ型糖尿病、多发性硬化症、类风湿性关节炎、银屑病、系统性红斑狼疮、哮喘、干燥综合症和强直性脊柱炎、葡萄膜炎、自身免疫性肾炎、自身免疫甲状腺炎、白塞氏病、扁平苔藓、多种呼吸道疾病、多种肝脏疾病以及多种心血管疾病等)。此外，抑制IL17和/或促进IL10的化合物还可作为免疫调节剂用于脓毒症、痤疮、椎间盘突出、腹腔疾病等与炎症相关的疾病的治疗。IL17还与肿瘤的发生密切相关，尤其是炎症相关的肿瘤。IL10对肿瘤的发生发展具有双向调节的作用。IL10可通过抑制促进肿瘤发生发展的炎性因子的产生以及通过活化肿瘤特异性CD8+T来发挥抗肿瘤作用[4]。因此抑制IL17和/或促进IL10的化合物还可作为免疫调节剂用于肿瘤治疗。
Th2细胞主要分泌细胞因子IL4。IL4具有多种生物学功能，在体液免疫和获得性免疫中发挥重要作用[6]。IL4能诱导B细胞、T细胞活化以及B细胞向浆细胞分化。此外，IL4还能抑制淋巴细胞凋亡、促进巨噬细胞的抗原提呈能力和提高杀伤肿瘤细胞的功能。因此，促进IL4的化合物可作为免疫调节剂用于抗肿瘤、抗感染(尤其是抗寄生虫感染)相关的疾病。
发明内容
本发明的目的在于提供一类倍半萜聚酮化合物、药物组合物及其用途。具体地，发明人从一株漆斑属真菌中发现并分离鉴定了一类倍半萜聚酮化合物，实验证明其具有免疫调节活性，可用于用于免疫相关疾病的预防和/或治疗。
本发明的第一方面提供了一类倍半萜聚酮化合物或其药学上可接受的盐，所述倍半萜聚酮类化合物如式(I)所示：
其中，R1选自：羟基，羰基，乙酰氧基；
R2选自：甲基，羟甲基，乙酰羟甲基，乙酰氧基，醛基，二甲氧基甲基；
R3选自：甲基，羟甲基，乙酰羟甲基，乙酰氧基，醛基，二甲氧基甲基；
或者R2，R3与苯环组成5元内酰胺环或内酯环；
R4，R5，R6，R7为碳原子，并且任一相邻基团间选自双键，其余基团间选自单键；
当R4，R5，R6，R7为碳原子，R5与R6间选自双键，其余基团间选自单键，R2选自羟甲基，R3选自醛基时，R1不可选自羟基或乙酰氧基。
进一步的，所述药学上可接受的盐为式(I)化合物与有机碱或无机碱形成的盐。
更进一步的，所述形成的盐为钠盐、钾盐、钙盐、铁盐、镁盐、锌盐、铝盐、钡盐或铵盐。
优选的，所述倍半萜聚酮类化合物选自式Ⅱ-式X的化合物，具体结构式如下：
本发明的第二方面提供了一种上述化合物的制备方法，包括：由产生如式(I)所示的倍半萜聚酮类化合物的微生物发酵后，再用色谱法分离后得到。
进一步的，所述微生物为漆斑属真菌。
进一步可选的，所述漆斑属真菌为ZLW0801-19，其保藏号为CGMCC No.19039。
本发明的第三方面还提供了制备免疫调节剂的上述式(I)化合物或其药学上可接受的盐。
进一步的，所述免疫调节剂用于免疫相关疾病的预防和/或治疗。
更进一步的，所述免疫调节剂用于防治抑制IL17和/或促进IL10是有益的疾病或适应症。
优选的，所述疾病或适应症选自银屑病、炎症性肠病、I型糖尿病、多发性硬化症、类风湿性关节炎、系统性红斑狼疮、哮喘、干燥综合症、强直性脊柱炎、器官移植免疫排斥、过敏、脓毒症、葡萄膜炎、自身免疫性肾炎、自身免疫甲状腺炎、白塞氏病、自身免疫性肝病、扁平苔藓、脓毒症、痤疮、椎间盘突出、腹腔疾病。
更进一步的，所述免疫调节剂用于防治促进IL4是有益的疾病或适应症。
优选的，所述疾病或适应症为寄生虫感染相关。
本发明的第四方面提供了一种用于免疫调节的药物组合物，包括上述倍半萜聚酮类化合物或其药学上可接受的盐以及药学上可接受的载体。
进一步可选的，所述盐为钠盐、钾盐、钙盐、铁盐、镁盐、锌盐、铝盐、钡盐、铵盐中的任意一种。
进一步可选的，在一个实施方式中药物组合物中含有的活性成份(即本发明化合物)的量可以根据患者的病情、医生诊断的情况特定的加以应用，活性化合物的量或浓度在一个较宽的范围内调节，所述式(I)化合物或其药学上可接受的盐的含量为组合物重量的1-90％。
进一步可选的，药学上可接受的载体包括稀释剂、润滑剂、粘合剂、崩解剂、稳定剂、溶剂等。本发明所述稀释剂包括但不限于淀粉、微晶纤维素、蔗糖、糊精、乳糖、糖粉、葡萄糖等；所述润滑剂包括但不限于硬脂酸镁、硬脂酸、氯化钠、油酸钠、月桂醇硫酸钠、泊洛沙母等；所述粘合剂包括但不限于水、乙醇、淀粉浆、糖浆、羟丙基甲基纤维素、羧甲基纤维素钠、海藻酸钠、聚乙烯吡咯烷酮等；所述崩解剂包括但不限于淀粉泡腾混合物即碳酸氢钠和枸橼酸、酒石酸、低取代羟丙基纤维素等；所述稳定剂包括但不限于多糖如金合欢胶、琼脂、藻酸、纤维素醚和羧甲基甲壳酯等；所述溶剂包括但不限于水、平衡的盐溶液等。
进一步可选的，所述药物组合物为口服制剂或注射剂；优选的，所述口服制剂包括但不限于普通片剂、分散片、肠溶片、颗粒、胶囊、滴丸、散剂、口服液或乳剂中的任意一种；优选的，所述注射剂选自小水针剂、输液剂或冻干粉针剂中的任意一种。
有益效果
本发明所述的倍半萜聚酮类化合物是从微生物发酵来源，便于大量发酵和工业化制备；活性实验首次发现该类化合物具有显著的免疫调节活性。
具体实施方式
下面将进一步的来举例说明本发明。需要指出的是，所述实施例说明了一些制备或使用方法，然而，要理解的是，这些实施例不限制本发明。本发明的保护范围以所附权利要求书记载的内容为准。
下列实施例中，质谱仪为美国Finnigan公司生产的LCQ-Advantage质谱仪。超导核磁共振仪为Bruker AV-400。薄层色谱用硅胶GF254和柱色谱硅胶(200-300目)均为青岛海洋化工厂产品。反相ODS填料50μm为日本YMC公司产品。中低压液相色谱仪为上海利穗电子科技有限公司产品。液相分离所使用色谱柱为Phenomenex Gemini C18 column(10.0×250mm,5μm)。液相色谱用甲醇和乙腈为色谱纯，水为双重蒸馏水，其他试剂均为分析纯。
实施例中显示的体外细胞水平的实验数据以平均值±标准差(Mean±SD)表示。对于比较两组数据间的差异，采用Two-tailed Student’s t test进行分析；比较多于2组的数据间的差异，采用One-way Anova进行分析。统计学差异采用以下标示：*代表P<0.05，**代表P<0.01，***代表P<0.001，****代表P<0.0001，ns代表差异不显著。采用GraphpadPrism 7.00和FlowJo V10(用于流式)分析获取的数据。
实施例1漆斑属真菌ZLW0801-19大量发酵及其样品前处理方法
(1)漆斑属真菌ZLW0801-19真菌菌株在25℃的马铃薯葡萄糖琼脂(PDA)斜面上培养5天。经PDA斜面活化后接种至4个含马铃薯葡萄糖(PDB)培养基的锥形瓶(250mL)中制备种子液，每个锥形瓶含有100mL PDB培养基，转速200rpm在25℃培养5天制备种子液。在24个锥形瓶(500mL)中进行发酵，每个锥形瓶中含有70g大米，首先向每个锥形瓶中加入蒸馏水(105mL)，将大米浸泡过夜，然后在120℃下高压灭菌30分钟。冷却至室温后，向每个锥形瓶接种5.0mL种子液，并在室温避光培养51天。
(2)将发酵物加入乙酸乙酯进行浸泡提取3次，将提取液减压浓缩至干，得到粗提物(81.7g)。
实施例2式(II)—式(X)化合物的制备
实施例1中乙酸乙酯粗提物(81.7g)利用硅胶柱层析，依次采用环己烷-乙酸乙酯(100:0,98:2,95:5,90:10,80:20,70:30,50:50,0:100,v/v)和甲醇进行洗脱，每个梯度洗脱体积6L，得到7个馏分样品(F1-F7)。馏分F5经中低压液相ODS柱层析，依次采用甲醇-水(70:30,80:20,90:10,and 100:0,v/v)洗脱，每个梯度洗脱体积2.5L，得到9个馏分样品(F5.1-F5.9)。馏分F5.2经中低压液相ODS柱层析，依次采用甲醇-水(60:40,70:30,80:20,90:10,v/v)洗脱，每个梯度洗脱体积0.7L，得到5个馏分样品(F5.2.1-F5.2.5)。馏分F5.2.4(387mg)经反相制备级HPLC制备(Cosmosil Packed C18 column)，使用流速为3mL/min的乙腈-水(50:50,v/v)进行洗脱，得到式(VIII)化合物(tR:53.6min,26.2mg)。将馏分F5.2.5(365mg)经反相制备级HPLC制备(Phenomenex,Packed C18 column)，使用流速为8mL/min的乙腈-水(55:45,v/v)进行洗脱，得到式(X)化合物(tR:86.4min,7.0mg)。馏分F5.3经凝胶柱LH-20柱层析，采用甲醇洗脱得到7个馏分(F5.3.1–F5.3.7)。馏分F5.3.7(144mg)经反相制备级HPLC制备(Cosmosil Packed C18 column)，使用流速为3mL/min的甲醇-水(75:25,v/v)进行洗脱，得到式(II)化合物(tR:63.7min,17.0mg)和式(III)化合物(tR:69.9min,17.5mg)。馏分F5.7经硅胶柱层析，依次采用环己烷-乙酸乙酯(90:10,85:15,80:20,75:25,70:30,60:40,50:50,0:100,v/v)洗脱，每个梯度洗脱体积1.0L，得到8个馏分样品(F5.7.1-F5.7.8)。馏分F5.7.4(62.1mg)经反相制备级HPLC制备(Cosmosil Packed C18 column)，使用流速为3mL/min的甲醇-水(82:18,v/v)进行洗脱，得到式(IV)化合物(tR:21.3min,12.1mg)。馏分F6经中低压液相ODS柱层析，依次采用甲醇-水(60:40,70:30,80:20,90:10,100:0,v/v)洗脱，每个梯度洗脱体积2.5L，得到7个馏分样品(F6.1-F6.7)。馏分F6.3经硅胶柱层析，依次采用环己烷-乙酸乙酯(75:25,70:30,60:40,50:50,0:100v/v)洗脱，每个梯度洗脱体积0.3L，得到6个馏分样品(F6.3.1-F6.3.6)。馏分F6.3.6(349.7mg)经反相制备级HPLC制备(Cosmosil Packed C18 column)，使用流速为3mL/min的乙腈-水(40:60,v/v)进行洗脱，得到式(VII)化合物(tR:17.5min,7.7mg)。馏分F6.4经中低压液相ODS柱层析，采用甲醇-水(70:30,v/v)洗脱，洗脱体积0.7L，得到5个馏分样品(F6.4.1-F6.4.5)。将馏分F6.4.2(1630mg)经反相制备级HPLC制备(Phenomenex,Packed C18 column)，使用流速为8mL/min的甲醇-水(70:30,v/v)进行洗脱，得到式(IX)化合物(tR:25.4min,4.0mg)。馏分F6.4.3(212.9mg)经反相制备级HPLC制备(Cosmosil Packed C18 column)，使用流速为3mL/min的乙腈-水(55:45,v/v)进行洗脱，得到式(V)化合物(tR:63.3min,10.3mg)和式(VI)化合物(tR:25.0min,10.1mg)。
理化常数如下：
式(II)化合物：无色片状晶体；
UV(CH3OH)λmax(logε)205(4.31),225(4.28),221(4.10),300(4.27)nm；ECD(c3.4×10–4M CH3OH)λmax(Δε)221(+1.86),245(+1.71),334(–0.55),306(–0.74)；IR(KBr)νmax3399,3137,2974,2929,2864,1616,1430,1293,1262,1117,1045cm–1；ESI-MS(positive)m/z 373[M+H]+,395[M+Na]+；ESI-MS(negative)m/z 371[M–H]–,743[2M–H]–；HR-ESI-MS(positive)m/z 373.2379[M+H]+(calcd.for C23H33O4,373.2379)，确定化合物分子式为C23H32O4；1H和13C NMR见表1。
式(III)化合物：淡黄色固体；
UV(CH3OH)λmax(logε)205(4.47),226(4.43),242(4.31),300(4.44)nm；IR(KBr)νmax3430,2961,2931,2868,1719,1622,1435,1265,1039cm–1；ESI-MS(positive)m/z 453[M+Na]+,883[2M+Na]+；ESI-MS(negative)m/z 429[M–H]–,859[2M–H]–；HR-ESI-MS(positive)m/z 431.2433[M+H]+(calcd.for C25H35O6,431.2434)，确定化合物分子式为C25H34O6；1H和13C NMR见表1。
式(IV)化合物：淡黄色油状；
UV(CH3OH)λmax(logε)205(4.52),226(4.47),242(4.31),298(4.45)nm；IR(KBr)νmax3279,2934,2867,1708,1618,1434,1267,1032cm–1；ESI-MS(positive)m/z 495[M+Na]+,967[2M+Na]+；ESI-MS(negative)m/z 471[M–H]–,943[2M–H]–；HR-ESI-MS(positive)m/z 495.2368[M+Na]+(calcd.forC27H36O7Na,495.2359)，确定化合物分子式为C27H36O7；1H和13C NMR见表1。
式(V)化合物：淡黄色油状；
UV(CH3OH)λmax(logε)205(4.37),225(4.35),239(4.18),300(4.35)nm；ECD(c 3.2×10–4M CH3OH)λmax(Δε)201(+1.34),235(+2.04),274(–0.80),324(+0.46)；IR(KBr)νmax3411,2929,2858,1618,1434,1386,1267,1240,1125,1050cm–1；ESI-MS(positive)m/z 387[M+H]+,409[M+Na]+；ESI-MS(negative)m/z 385[M–H]–,771[2M–H]–；HR-ESI-MS(positive)m/z 409.2009[M+Na]+(calcd.for C23H30O5Na,409.2015)，确定化合物分子式为C23H30O5；1H和13C NMR见表2。
式(VI)化合物：淡黄色固体；
UV(CH3OH)λmax(logε)206(4.36),226(4.30),240(4.16),299(4.33)nm；ECD(c 5.8×10–4M CH3OH)λmax(Δε)224(+0.99),249(+3.46),302(–0.76),361(–1.02)；IR(KBr)νmax3399,2934,2850,1617,1386,1267,1245,1125,1050,988cm–1；ESI-MS(positive)m/z 455[M+Na]+,895[2M+Na]+；ESI-MS(negative)m/z 431[M–H]–,863[2M–H]–；HR-ESI-MS(positive)m/z 455.2415[M+Na]+(calcd.for C25H36O6Na,455.2410)，确定化合物分子式为C25H36O6；1H和13C NMR见表2。
式(VII)化合物：淡绿色固体；
UV(CH3OH)λmax(logε)215(4.57),262(4.06),305(3.27)nm；IR(KBr)νmax3385,2929,2863,1675,1452,1386,1262cm–1；ESI-MS(positive)m/z 386[M+H]+,793[2M+Na]+；ESI-MS(negative)m/z 769[2M–H]–；HR-ESI-MS(positive)m/z 386.2340[M+H]+(calcd.for C23H32NO4,386.2331)，确定化合物分子式为C23H31NO4；1H和13C NMR见表2。
式(VIII)化合物：淡绿色固本；
UV(CH3OH)λmax(logε)206(4.44),223(4.46),240(4.42),298(4.33)nm；ECD(c 6.0×10–4M CH3OH)λmax(Δε)204(+7.00),247(+18.5),330(+1.81)；IR(KBr)νmax3283,2970,2925,2867,1621,1618,1430,1267,1005cm–1；ESI-MS(positive)m/z 409[M+Na]+,795[2M+Na]+；ESI-MS(negative)m/z385[M–H]–,771[2M–H]–；HR-ESI-MS(positive)m/z 387.2176[M+H]+(calcd.for C23H31O5,387.2176)，确定化合物分子式为C23H30O5；1H和13C NMR见表3。
式(IX)化合物：白色固体；
UV(CH3OH)λmax(logε)206(4.39),226(4.06),289(3.69)nm；ECD(c 6.4×10–4M CH3OH)λmax(Δε)220(+3.81),236(+3.09),246(+3.74),323(–0.54)；IR(KBr)νmax3301,2961,2872,1628,1462,1284,1125,1076cm–1；ESI-MS(positive)m/z 389[M+H]+,411[M+Na]+；ESI-MS(negative)m/z 387[M–H]–,775[2M–H]–；HR-ESI-MS(positive)m/z 389.2329[M+H]+(calcd.for C23H33O5,389.2328)，确定化合物分子式为C23H32O5；1H和13C NMR见表3。
式(X)化合物：白色固体；
UV(CH3OH)λmax(logε)206(4.41),227(4.09),290(3.76)nm；ECD(c 2.9×10–4M CH3OH)λmax(Δε)220(+5.47),235(+4.19),246(+5.58),320(–1.30)；IR(KBr)νmax3479,29743,2881,1740,1623,1489,1270,1045cm–1；ESI-MS(positive)m/z 453[M+Na]+；ESI-MS(negative)m/z 429[M–H]–,HR-ESI-MS(positive)m/z 453.2246[M+Na]+(calcd.for C25H34O6Na,453.2353)，确定化合物分子式为C25H34O6；1H和13C NMR见表3。
表1式(II)—式(IV)化合物的13C NMR及1H NMR数据和归属
aThe data recorded in DMSO-d6(1H NMR for 300MHz,13C NMR for 75MHz)
bThe data recorded in DMSO-d6(1H NMR for 400MHz,13C NMR for 100MHz)
表2式(V)—式(VII)化合物的13C NMR及1H NMR数据和归属
aThe data recorded in DMSO-d6(1H NMR for 300MHz,13C NMR for 75MHz)
bThe data recorded in DMSO-d6(1H NMR for 400MHz,13C NMR for 100MHz)
表3式(VIII)—式(X)化合物的13C NMR及1H NMR数据和归属
aThe data recorded in DMSO-d6(1H NMR for 300MHz,13C NMR for 75MHz)
实施例3倍半萜聚酮类化合物式(II)—式(X)对IL17表达的影响
T细胞分化后产生特定细胞因子，如Th17产生细胞因子IL17，Th2产生细胞因子IL4，Tr1产生细胞因子IL10。IL17-GFP小鼠、IL4-eGFP小鼠和IL10-eGFP小鼠(均引自JAX公司)是带有绿色荧光报告基因(GFP)的转基因小鼠，其在T细胞分化后产生的特定细胞因子的基因下游连接上GFP荧光蛋白编码序列。因此可用荧光探测系统检测GFP的表达量来衡量细胞因子的表达水平。
提取荧光报告小鼠IL17-GFP小鼠的原代脾脏淋巴细胞，在Th17分化条件下与化合物共培养，通过流式细胞术检测IL17-GFP水平来评价化合物对IL17表达的影响(此方法使用原代淋巴细胞更好模拟复杂的生理过程；使用GFP小鼠和流式细胞术使实验简便，重复性好且结果可靠)。具体实验步骤如下：
Anti-mouse CD3 Ab(antibody，抗体)包板：在96孔板中加入IMDM培养基稀释的终浓度为10μg/mL的anti-mouse CD3 Ab，37℃孵育2小时。
制备单细胞悬液：无特定病原体(SPF)环境下饲养的IL17-GFP小鼠，颈椎脱臼处死，取脾脏置于IMDM培养基中，用灭菌的病理玻片在超净台中磨碎脾脏，磨碎后的细胞悬液用40μm cell strainer滤网过滤至离心管；后离心(4℃，1400rpm，7分钟)，弃上清，加红细胞裂解液，混匀，室温静置5分钟，后加IMDM终止裂解红细胞；40μm cell strainer滤网过滤后再离心(4℃，1400rpm，7分钟)，弃上清，用含10％FBS的IMDM重悬细胞；细胞稀释100倍，显微镜下细胞计数，根据计数结果，配成1×106个/mL(终浓度)的细胞悬液。
加入Th17细胞分化诱导因子：anti-mouse CD28 Ab(1μg/mL)，rhTGFb1.2(0.25ng/mL)，rmIL6(40ng/mL)，anti-mouse IL4(5μg/mL)，anti-mouse IFNγ(5μg/mL)(此处细胞因子均为终浓度)。
待检测样本稀释：用含10％FBS的IMDM将化合物稀释成10μM(终浓度)；将抑制IL17的阳性化合物SR2211稀释成1μM(终浓度)。
铺板：将包板的抗体吸去，用IMDM洗一遍，每孔加入100μL细胞悬液和100μL终浓度样本溶液共培养(如100μL 4×106个/mL浓度的细胞悬液和100μL 20μM化合物共培养，培养体系中细胞终浓度为2×106个/mL，化合物浓度为10μM)。
细胞培养：样本溶液和细胞置于37℃，5％的CO2的湿润培养箱中共培养72小时。
细胞表面染色和流式检测：收取培养的细胞于流式管，加入3mL预冷的PBS，离心(4℃，1400rpm，7分钟)，弃上清，后在50μL细胞悬液中加入0.25μL APC anti-mouse CD4抗体表面染色，4℃避光放置20分钟。后用1mL预冷的PBS重悬细胞，补2mL PBS，再离心(4℃，1400rpm，7分钟)，弃上清，每管加200μL PBS，流式检测分析GFP+的细胞占CD4+细胞的比率。
其中IMDM培养基和胎牛血清(FBS)购自Gibco公司；anti-mouse CD28 Ab，anti-mouse CD3 Ab，anti-mouse IL4，anti-mouse IFNγ，APC anti-mouse CD4购自Sungene公司；rmIL6购自Peprotech公司；rhTGFb1.2购自R&D公司；红细胞裂解液购自Tiangen公司；PBS购自Solarbio公司。
采用公式：(DMSO组GFP+占CD4+的比率-化合物组GFP+占CD4+的比率)/DMSO组GFP+占CD4+的比率×100％来计算化合物对IL17表达的相对抑制活性(Relative InhibitionActivity)。
结果如表4所示：脾脏淋巴细胞向Th17细胞分化条件下，本发明化合物式(II)、式(III)、式(IX)和式(X)对IL17表达的相对抑制活性显著增强。这表明，本发明化合物式(II)、式(III)、式(IX)和式(X)具有抑制IL17表达的效果，可用于防治免疫相关疾病尤其是IL17介导的免疫性疾病。
表4式(II)—式(X)化合物对IL17表达影响(10μM)
实施例4倍半萜聚酮类化合物式(II)—式(X)对IL4表达的影响
提取荧光报告小鼠IL4-eGFP小鼠的原代脾脏淋巴细胞，在Th2分化条件下与化合物共培养，通过流式细胞术检测IL4-GFP水平来评价化合物对IL4表达的影响。Th2使用的培养基为RPMI-1640；细胞密度为2×106个/mL；使用的分化条件为：anti-mouse CD28 Ab(1μg/mL)，rmIL2(2ng/mL)，rmIL4(40ng/mL)，Anti-mouse IFNγ(10μg/mL)。其他Th2分化的实验步骤同实施例3中的Th17分化一致。
其中rmIL4，rmIL2购自Peprotech公司；RPMI-1640培养基购自Sigma公司。
在评价化合物对IL4的影响时，采用公式：化合物组GFP+占CD4+的比率/DMSO组GFP+占CD4+的比率×100％来计算化合物对IL4的相对活性(Relative Activity)。
具体结果如表5所示：脾脏淋巴细胞向Th2细胞分化条件下，本发明化合物式(II)、式(VIII)、式(IX)和式(X)对IL4的相对活性显著增强。这表明本发明化合物式(II)、式(VIII)、式(IX)和式(X)具有促进IL4表达的效果，可用于抗寄生虫感染。
表5式(II)—式(XII)化合物对IL4表达影响(10μM)
| Compounds | Relative Activity(％)(10μM) | P-value |
| 式II | 169.77±4.65 | **** |
| 式III | 101.63±5.82 | ns |
| 式IV | 89.77±2.79 | ns |
| 式V | 88.61±2.56 | ns |
| 式VI | 87.68±1.63 | ns |
| 式VII | 87.68±2.56 | ns |
| 式VIII | 247.21±1.16 | **** |
| 式IX | 216.75±3.26 | **** |
| 式X | 346.98±2.33 | **** |
实施例5倍半萜聚酮类化合物式(II)—式(X)对IL10表达的影响
提取分选荧光报告小鼠IL10-eGFP小鼠的原代脾脏淋巴细胞，在Tr1分化条件下与化合物共培养，通过流式细胞术检测IL10-eGFP水平来评价化合物对IL10表达的影响。Tr1使用的培养基为RPMI-1640；细胞密度为1×106个/mL；使用的分化条件为：anti-mouseCD28 Ab(1μg/mL)，rmIL27(50ng/mL)，rhTGFb1.2(0.5ng/mL)。其他Tr1分化的实验步骤同实施例3中的Th17分化一致。
其中rmIL27购自Biolegend公司；RPMI-1640培养基购自Sigma公司。
在评价化合物对IL10的影响时，采用公式：化合物组GFP+占CD4+的比率/DMSO组GFP+占CD4+的比率×100％来计算化合物对IL10的相对活性(Relative Activity)。
具体结果如表6所示：脾脏淋巴细胞向Tr1细胞分化条件下，本发明化合物式(II)、式(IV)、式(V)、式(VI)、式(VII)、式(VIII)、式(IX)和式(X)对IL10表达的相对活性显著增强。这表明上述化合物具有促进IL10表达的效果，可发挥广谱的抗炎作用，用于抗炎和自身免疫性疾病。
表6式(II)—式(X)化合物对IL10表达影响(20μM)
| Compounds | Relative Activity(％)(20μM) | P-value |
| 式II | 265.43±7.25 | **** |
| 式III | 112.78±4.28 | ns |
| 式IV | 117.79±5.93 | * |
| 式V | 114.74±1.95 | * |
| 式VI | 115.47±3.49 | * |
| 式VII | 116.12±5.19 | * |
| 式VIII | 274.15±4.40 | **** |
| 式IX | 236.75±10.91 | **** |
| 式X | 332.97±3.83 | **** |
综合上述实施例3、4和5的结果可知：倍半萜聚酮类化合物具有抑制IL17、促进IL4和促进IL10表达的活性，可用于免疫性疾病的防治。
本发明内容仅仅举例说明了要求保护的一些具体实施方案，其中一个或更多个技术方案中所记载的技术特征可以与任意的一个或多个技术方案相组合，这些经组合而得到的技术方案也在本申请保护范围内，就像这些经组合而得到的技术方案已经在本发明公开内容中具体记载一样。
参考文献：
[1]Horwitz D A,Fahmy T M,Piccirillo C A,et al.Rebalancing immunehomeostasis to treat autoimmune diseases.Trends Immunol,2019,40(10):888-908.
[2]Maddur M S,Miossec P,Kaveri S V,et al.Th17 cells.The AmericanJournal of Pathology,2012,181(1):8-18.
[3]Patel D D,Kuchroo V K.Th17 cell pathway in human immunity:Lessonsfrom genetics and therapeutic interventions.Immunity,2015,43(6):1040-1051.
[4]Bedke T,Muscate F,Soukou S,et al.Il-10-producing t cells and theirdual functions.Semin Immunol,2019,44:101335.
[5]Roncarolo M G,Gregori S,Bacchetta R,et al.The biology of tregulatory type 1 cells and their therapeutic application in immune-mediateddiseases.Immunity,2018,49(6):1004-1019.
[6]Ho I C,Miaw S C.Regulation of il-4 expression in immunity anddiseases.Advances in Experimental Medicine and Biology,2016,941:31-77.
Claims (17)
1.一类倍半萜聚酮化合物或其药学上可接受的盐，其特征在于，所述倍半萜聚酮化合物如式(I)所示：
其中，R1选自：羟基，乙酰氧基，或＝O；
R2选自：甲基，羟甲基，乙酰羟甲基，醛基，或二甲氧基甲基；
R3选自：甲基，羟甲基，乙酰羟甲基，或醛基；
或者R2，R3与苯环组成5元内酰胺环或内酯环；
R4，R5，R6，R7为碳原子，并且任一相邻基团间选自双键，其余基团间选自单键；
当R4，R5，R6，R7为碳原子，R5与R6间选自双键，其余基团间选自单键，R2选自羟甲基，R3选自醛基时，R1不可选自羟基或乙酰氧基。
2.根据权利要求1所述一类倍半萜聚酮化合物或其药学上可接受的盐，其特征在于，所述药学上可接受的盐为式(I)化合物与有机碱或无机碱形成的盐。
3.根据权利要求2所述的倍半萜聚酮类化合物或其药学上可接受的盐，其特征在于，所述形成的盐为钠盐、钾盐、钙盐、铁盐、镁盐、锌盐、铝盐、钡盐或铵盐。
4.根据权利要求1-3中任一项所述的倍半萜聚酮类化合物或其药学上可接受的盐，其特征在于，所述倍半萜聚酮类化合物选自式Ⅱ-式X的化合物，具体结构式如下：
5.根据权利要求1-4中任一项所述倍半萜聚酮化合物或其药学上可接受的盐的制备方法，其特征在于，包括：由产生如式(I)所示的倍半萜聚酮类化合物的微生物，经发酵后再用色谱法分离后得到。
6.根据权利要求5所述的制备方法，其特征在于，所述微生物为漆斑属真菌。
7.根据权利要求6所述的制备方法，其特征在于，所述漆斑属真菌为ZLW0801-19，其保藏号为CGMCC No.19039。
8.权利要求1-4中任意一项所述倍半萜聚酮类化合物或其药学上可接受的盐在制备免疫调节剂中的用途。
9.根据权利要求8所述的用途，其特征在于，所述免疫调节剂用于免疫相关疾病的预防和/或治疗。
10.根据权利要求9所述的用途，其特征在于，所述的免疫相关疾病的预防和/或治疗是防治抑制IL17和/或促进IL10是有益的疾病或适应症。
11.根据权利要求10所述的用途，其特征在于，所述疾病或适应症选自银屑病、炎症性肠病、I型糖尿病、多发性硬化症、类风湿性关节炎、系统性红斑狼疮、哮喘、干燥综合症、强直性脊柱炎、器官移植免疫排斥、过敏、脓毒症、葡萄膜炎、自身免疫性肾炎、自身免疫甲状腺炎、白塞氏病、自身免疫性肝病、药物性肝损伤、扁平苔藓、痤疮、椎间盘突出、腹腔疾病。
12.根据权利要求9所述的用途，其特征在于，所述的免疫相关疾病的预防和/或治疗是防治促进IL4是有益的疾病或适应症。
13.根据权利要求12所述的用途，其特征在于，所述疾病或适应症为寄生虫感染相关。
14.一种用于免疫调节的药物组合物，其特征在于，包括权利要求1-4中任意一项所述倍半萜聚酮化合物或其药学上可接受的盐以及药学上可接受的载体。
15.根据权利要求14所述的药物组合物，其特征在于，所述倍半萜聚酮化合物或其药学上可接受的盐的含量为组合物重量的1-90％。
16.根据权利要求14-15所述的药物组合物，其特征在于，所述药物组合物为口服制剂或注射剂。
17.根据权利要求16所述的药物组合物，其特征在于，所述口服制剂选自普通片剂、分散片、肠溶片、颗粒、胶囊、滴丸、散剂、口服液或乳剂，所述注射剂为小水针剂、输液剂或冻干粉针。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210626229.0A CN114956974B (zh) | 2022-06-02 | 2022-06-02 | 一类倍半萜聚酮化合物、药物组合物及其用途 |
| PCT/CN2023/097906 WO2023232125A1 (zh) | 2022-06-02 | 2023-06-01 | 一类倍半萜聚酮化合物、药物组合物及其用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210626229.0A CN114956974B (zh) | 2022-06-02 | 2022-06-02 | 一类倍半萜聚酮化合物、药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114956974A true CN114956974A (zh) | 2022-08-30 |
| CN114956974B CN114956974B (zh) | 2023-10-31 |
Family
ID=82960659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210626229.0A Active CN114956974B (zh) | 2022-06-02 | 2022-06-02 | 一类倍半萜聚酮化合物、药物组合物及其用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114956974B (zh) |
| WO (1) | WO2023232125A1 (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023232125A1 (zh) * | 2022-06-02 | 2023-12-07 | 暨南大学 | 一类倍半萜聚酮化合物、药物组合物及其用途 |
| WO2023232123A1 (zh) * | 2022-06-02 | 2023-12-07 | 暨南大学 | 一类倍半萜聚酮化合物作为免疫调节剂在防治免疫性疾病的用途 |
| WO2023232126A1 (zh) * | 2022-06-02 | 2023-12-07 | 暨南大学 | 一个倍半萜聚酮化合物用于防治肺动脉高压的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016080796A2 (ko) * | 2014-11-19 | 2016-05-26 | 한국생명공학연구원 | 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도 |
| CN115040507A (zh) * | 2022-06-02 | 2022-09-13 | 暨南大学 | 一类倍半萜聚酮化合物作为免疫调节剂在防治免疫性疾病的用途 |
| CN114956974B (zh) * | 2022-06-02 | 2023-10-31 | 暨南大学 | 一类倍半萜聚酮化合物、药物组合物及其用途 |
| CN116444475A (zh) * | 2023-03-27 | 2023-07-18 | 云南大学 | 一种倍半萜类化合物及其制备方法和应用 |
-
2022
- 2022-06-02 CN CN202210626229.0A patent/CN114956974B/zh active Active
-
2023
- 2023-06-01 WO PCT/CN2023/097906 patent/WO2023232125A1/zh unknown
Non-Patent Citations (3)
| Title |
|---|
| QIUYAN LIU等: "Albaconol, a Plant-Derived Small Molecule, Inhibits Macrophage Function by Suppressing NF-κB Activation and Enhancing SOCS1 Expression", 《CELLULAR & MOLECULAR IMMUNOLOGY》 * |
| 邝润桥: "一株湿地来源漆斑属真菌次生代谢产物研究", 《暨南大学硕士学位论文》 * |
| 郭立敏等: "天然倍半萜类化合物抗炎作用机制的研究进展", 《中国中药杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023232125A1 (zh) * | 2022-06-02 | 2023-12-07 | 暨南大学 | 一类倍半萜聚酮化合物、药物组合物及其用途 |
| WO2023232123A1 (zh) * | 2022-06-02 | 2023-12-07 | 暨南大学 | 一类倍半萜聚酮化合物作为免疫调节剂在防治免疫性疾病的用途 |
| WO2023232126A1 (zh) * | 2022-06-02 | 2023-12-07 | 暨南大学 | 一个倍半萜聚酮化合物用于防治肺动脉高压的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023232125A1 (zh) | 2023-12-07 |
| CN114956974B (zh) | 2023-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114956974B (zh) | 一类倍半萜聚酮化合物、药物组合物及其用途 | |
| WO2023232123A1 (zh) | 一类倍半萜聚酮化合物作为免疫调节剂在防治免疫性疾病的用途 | |
| EP2246047B1 (en) | Use of lanostane derivatives in treating cachexia | |
| KR101446179B1 (ko) | 바우미 상황버섯 유래의 폴리페놀 추출물을 유효성분으로 함유하는 염증질환의 예방 및 치료용 조성물 | |
| Xiong et al. | Investigation of effects of farrerol on suppression of murine T lymphocyte activation in vitro and in vivo | |
| RU2155772C2 (ru) | Циклопептолид, штамм гриба, способ получения циклопептолида, терапевтический состав | |
| EA002354B1 (ru) | Производные циклопентенона | |
| JPWO2003051382A1 (ja) | アポトーシスを誘導する方法およびそのための組成物 | |
| WO2012103777A1 (zh) | 一种从红曲中分离的化合物、其制备方法及用途 | |
| CN111499649A (zh) | 一种具有抗肿瘤活性的苯并二呋喃酮类化合物、制备方法及其用途 | |
| US20040229852A1 (en) | Pharmaceutical composition for enhancing immunity, and extract of Poria | |
| JP2000154151A (ja) | 免疫抑制剤 | |
| CN114573655B (zh) | 胆酸衍生物及其制备方法 | |
| WO2009141786A2 (en) | Anti-inflammatory compounds | |
| JP2005501079A (ja) | 気管支呼吸困難の治療及び療法のための草本組成物 | |
| TW202031257A (zh) | 乳酸菌的代謝產物及其用於護肺的用途 | |
| EP1535619B1 (en) | Poria extract devoid of secolanostane derivatives comprising lanostane derivatives for immunity enhancement | |
| JP3719689B2 (ja) | 新規物質トリプロスタチン、その製造方法、細胞周期阻害剤および抗腫瘍剤 | |
| WO2012101564A2 (en) | Anti-inflammatory compounds | |
| CN114349814B (zh) | 一种木栓烷型化合物及其制备方法与用途 | |
| CN114524857B (zh) | 胆酸衍生物及其应用 | |
| CN113527381B (zh) | 一种类葡萄糖衍生物及其制备方法和应用 | |
| CN109652468B (zh) | 一种抗肿瘤化合物的制备方法及其应用 | |
| KR0145942B1 (ko) | 신규 항암제 조성물 | |
| CN109293494B (zh) | 一种红树内生真菌来源的1,4-萘醌类化合物及其制备方法和在制备抗炎药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |